Efficacy of Empagliflozin on Acute Coronary Syndrome with Type 2 Diabetes: Open-label Randomized Controlled Trial - Empagliflozin on Acute Coronary Syndrome

The Sakakibara Heart Institute of Okayama0 个研究点目标入组 100 人开始时间: 2016年2月10日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Patients with hypersensitivity to the components of Empagliflozin 2) Patients with severe ketosis, diabetic coma or pre-coma 3) Patients with severe infection, before and after surgery, severe trauma 4) Patients with dehydration 5) Patients with uncontrolled hypertension (sBP>180mmHg under medication) or low blood pressure (sBP<85mmHg) 6) Patients with advanced renal dysfunction or patients on dialysis (eGFR<30) 7) Patients with severe hepatic dysfunction 8) Patients with congenital heart disease or valvular disease 9) Patients with severe complications such as malignant neoplasm and severe infections 10) Patients with a history of heart transplant 11) Patients with drug or alcohol dependence 12) Patients with urinary tract or genital infection 13) Patients with pregnancy, or possibility and hope 14) Patients who have participated in clinical studies using other investigational or unapproved medicines within 3 months 15) Patients whom physician in charge considered inappropriate for the study

发起方

The Sakakibara Heart Institute of Okayama